Expression of p53, p16, PTEN, and c-myc Gene with Cisplatin Treatment in Cisplatin Resistant Ovarian Cancer Cell Line / 대한산부인과학회잡지

ABSTRACT

OBJECTIVE: The chemotherapeutic agent Cisplatin (cis-diammminedichloroplatinum (II)) is particularly effective against ovarian carcinoma, however, its clinical success is limited by recurrent drug resistant tumors. It is mandatory to reveal the mechanism of cisplatin resistance for the ovarian cancer treatment or prognosis. This study assessed the expression of p53, p16, PTEN, and c-myc genes with cisplatin treatment in human ovarian cancer cell lines; cisplatin-sensitive (A2780) and cisplatin-resistant (A2780/CP70) ovarian cancer cell line to elucidate the mechanism of cisplatin resistance. METHODS: Cytotoxic assay for cisplatin was performed in cisplatin-sensitive ovarian cancer cell line, A2780 and cisplatin-resistant ovarian cancer cell line, A2780/CP70. After cisplatin treatment, expression of p53, p16, PTEN, c-myc was analyzed by Western blot analysis. RESULTS: PTEN expression was significantly about 30% higher in A2780 than in A2780/CP70. p16 expression was defective in both cell lines. p53 and c-myc expression was no difference in cancer cell lines. After cisplatin treatment, the expression of p53, PTEN, c-myc genes increased 2-3 times in both cell lines. CONCLUSION: Relatively lower expression of PTEN was detected in A2780/CP70 suggesting that PTEN expression might play a role in the development of cisplatin resistance in ovarian cancer cell line, A2780/ CP70.